The FDA has approved Tecentriq and Tecentriq Hybreza in combination with lurbinectedin for the maintenance treatment of ES-SCLC, reducing the risk of disease progression or death by 46% and risk of death by 27%. This regimen is recommended as a preferred option in NCCN Guidelines for SCLC. The approval is based on the phase III IMforte study, showing improved progression-free and overall survival compared to standard induction treatment. This marks the first combination therapy for ES-SCLC maintenance treatment, providing a new proactive approach to managing this aggressive disease. Tecentriq has previously been approved for ES-SCLC in combination with chemotherapy. A new combination therapy has shown promising results in reducing the risk of disease progression or death by 46% and the risk of death by 27% in a pivotal phase III study. This therapy is the first and only combination treatment for first-line maintenance of ES-SCLC, addressing the high relapse rate in this type of cancer. The regimen is recommended in the National Comprehensive Cancer Network Guidelines for SCLC. This treatment is used by Jazz Pharmaceuticals under license. The study results were presented at the ASCO Annual Meeting and published in Clinical Lung Cancer.

Read more at Combination Therapy Reduces Risk of Disease Progression and Death in Small Cell Lung Cancer Study – GlobeNewswire

First-Line Maintenance Treatment for ES-SCLC Shows Significant Benefits – GlobeNewswire

NCCN Guidelines Recommend Regimen for Small Cell Lung Cancer – GlobeNewswire: FDA approves Roche’s Tecentriq plus lurbinectedin as